MARIA KRITIKOU

Ms. MARIA KRITIKOU

National and Kapodistrian University of Athens, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
XAXenofon Aggelidis
Xenofon Aggelidis
MKMARIA KRITIKOU
MARIA KRITIKOU
Michael MakrisMichael Makris
Michael Makris
MMMichael Miligkos
Michael Miligkos
NPniki papapostolou
niki papapostolou
PXPARASKEVI XEPAPADAKI
PARASKEVI XEPAPADAKI
Respiratory allergic diseases affect over 500 million people globally and pose a substantial burden in terms of morbidity, mortality, and healthcare costs. Restrictive factors such as geographical disparities, infectious pandemics, limitations in resources, and shortages of allergy specialists in underserved areas impede effective management. Telemedicine encompasses real-time visits, store-and-forward option triage, and computer-based technologies for establishing efficient doctor-patient communication. Recent advances in digital technology, including designated applications, informative materials, digital examination devices, wearables, digital inhalers, and integrated platforms, facilitate personalized and evidence-based care delivery. The integration of telemonitoring in respiratory allergy care has shown beneficial effects on disease control, adherence, and quality of life. While the COVID-19 pandemic accelerated the adoption of telemedicine, certain concerns regarding technical requirements, platform quality, safety, reimbursement, and regulatory considerations remain unresolved. The integration of artificial intelligence (AI) in telemonitoring applications holds promise for data analysis, pattern recognition, and personalized treatment plans. Striking the balance between AI-enabled insights and human expertise is crucial for optimizing the benefits of telemonitoring. While telemonitoring exhibits potential for enhancing patient care and healthcare delivery, critical considerations have to be addressed in order to ensure the successful integration of telemonitoring into the healthcare landscape.

30 September 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
NPNikolaos Pyrpyris
Nikolaos Pyrpyris
MKMARIA KRITIKOU
MARIA KRITIKOU
XAXenofon Aggelidis
Xenofon Aggelidis
IMIoanna Manolaraki
Ioanna Manolaraki
Michael MakrisMichael Makris
Michael Makris
PXPARASKEVI XEPAPADAKI
PARASKEVI XEPAPADAKI
The European Anaphylaxis Registry (NORA) was designed in order to create a comprehensive Anaphylaxis Registry regarding anaphylactic reactions characteristics and management in several European countries, including Greece. This study aims to analyze Greek data obtained in the NORA framework and describe anaphylaxis’ characteristics in this pediatric cohort. An online questionnaire was filled out by the Allergy Unit of the 2nd Pediatric Department of NKUA, regarding reported anaphylaxis characteristics. A total of 284 pediatric patients were analyzed. Patients were predominantly male. A previous, mild reaction (59.5%) to the same allergen was documented in 44.4% of patients. The most common system involved was skin and/or mucosa, followed by the respiratory system. Food was the most common eliciting factor (82.4%). First line treatment was most administered solely by a healthcare professional, followed by a lay person (38.7%). Auto injected adrenaline use by lay persons was third in frequency (29.2%). Most patients received post-reaction counseling and appropriate drug prescription. This study provides insight in anaphylactic cases’ characteristics and management in a Greek pediatric cohort. A low rate of adrenaline autoinjector administration was noted in lay people; however, drug prescription and counseling following the reaction could help increase correct acute anaphylaxis management in the future.

Verified
Journal Article
Open access
PDF file
NKNikolaos Katsanakis
Nikolaos Katsanakis
PXPARASKEVI XEPAPADAKI
PARASKEVI XEPAPADAKI
IKIoannis-Alexios Koumprentziotis
Ioannis-Alexios Koumprentziotis
PVPavlos Vidalis
Pavlos Vidalis
JLJohn Lakoumentas
John Lakoumentas
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
Background/Objectives: The importance of non-invasive biomarkers for the diagnosis and monitoring of allergic diseases in childhood is currently unknown. From this perspective, data on the role of the total (t) immunoglobulin E (IgE) in relation to different allergic diseases across different age groups until adulthood remain unclear. The potential association of tIgE levels with types of allergic diseases diagnosed in an specialized tertiary allergy center, in relation to sex and the age group spanning from birth to 20 years, are evaluated in the present study. Methods: In this retrospective study, the tIgE values were obtained from children assessed for allergy-associated symptoms in our department from January 2015 to December 2020. The tIgE values were analyzed in relation to age and diagnosis. Results: Data from 2127 patients (1321 boys (62.1%)), with a median age of 6.31 (3.01–9.95) years, were available. The tIgE median values for the studied population were 132 (37.7–367.5) kU/lt. The tIgE values showed a significant increase from 0–2 years to 2–5 and 5–12 years, but not from 5–12 to 12–20 years. Boys exhibited significantly higher tIgE values compared to girls. Furthermore, the tIgE levels were significantly increased in children with asthma, allergic rhinitis, food allergy, and atopic dermatitis in comparison to children without these diagnoses. Conclusions: The total IgE values exhibit a significant and progressive longitudinal increase in children with allergic diseases, particularly notable in the 0–2 and 5–12 age groups, in boys, and in children diagnosed with atopic conditions.

12 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
XAXenophon Aggelidis
Xenophon Aggelidis
MKMARIA KRITIKOU
MARIA KRITIKOU
Michael MakrisMichael Makris
Michael Makris
MMMichael Miligkos
Michael Miligkos
NPniki papapostolou
niki papapostolou
PXPARASKEVI XEPAPADAKI
PARASKEVI XEPAPADAKI
Respiratory allergic diseases, affect over 500 million people globally and pose a substantial burden in terms of morbidity, mortality, and healthcare costs. Restrictive factors such as geographical disparities, infectious pandemics, limitations in resource, and shortage of allergy specialists in underserved areas, impede effective management. Moreover, the well-established suboptimal adherence in patients with respiratory allergies, contribute further to the accelerated loss of disease control. Telemedicine encompasses real-time visits, store-and-forward options triage, and computer-based technologies for establishing and efficient doctor-patient communication. Recent advances in digital technology, including designated applications, informative materials, digital examination devices, wearables, digital inhalers, and integrated platforms, facilitate personalized and evidence-based care delivery. The integration of telemonitoring in respiratory allergy care has shown beneficial effects in disease control, adherence, and quality of life. While the COVID-19 pandemic accelerated the adoption of telemedicine, certain concerns regarding technical requirements, platform quality, safety, reimbursement, and regulatory considerations remain unresolved. Challenges in telemonitoring implementation further include ensuring effective doctor-patient collaboration, addressing privacy concerns, and establishing cost-effective models. The integration of artificial intelligence (AI) in telemonitoring applications holds promise for data analysis, pattern recognition, and personalized treatment plans. Striking the balance between AI-enabled insights and human expertise is crucial for optimizing the benefits of telemonitoring. This overview reports the up- to- date telemedicine approaches in managing patients with respiratory allergies. While telemonitoring exhibits potential in enhancing patient care and healthcare delivery, critical considerations have to be addressed in order to ensure the successful integration of telemonitoring into the healthcare landscape.

1 January 2026 in Indoor Air
Verified
Journal Article
Open access
PDF file
KSKristina Siemens
Kristina Siemens
TATamar Abramidze
Tamar Abramidze
CACezmi Akdis
Cezmi Akdis
MAMubeccel Akdis
Mubeccel Akdis
IAIsabella Annesi-Maesano
Isabella Annesi-Maesano
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
Air pollution has been recognised as the single biggest environmental threat to human health within the European Union (EU). Indoor air pollution has received less attention than outdoor air pollution, even though we spend most of our time indoors. It is associated with a variety of short‐ and long‐term health effects. These include allergies and asthma with a key role for the exposure to bioaerosols and synergistic interactions between chemical and biological pollutants. Given the dramatic rise of allergic diseases, the prevention of symptom exacerbations and the new onset of disease are of great importance, particularly for vulnerable populations such as children. The lack of a unified EU‐wide approach involving all stakeholders represents a major unmet need. The EU‐funded IDEAL Cluster comprises seven research projects to advance knowledge on indoor air quality (IAQ) and its impact on health, inform policies and thus promote healthier indoor environments. The ‘SynAir‐G’ project forms part of this cluster and was launched in 2022 with the participation of 18 partners from 11 countries. It focuses on schools to explore synergistic interactions between chemical and biological pollutants based on the hypothesis that these modulate major health effects. SynAir‐G includes the development of low‐cost sensors, collection of health outcomes, modelling of pollution dynamics and the development of mitigation solutions. The knowledge will be circulated to all stakeholders and the public aiming to establish standards and health‐based guidelines. The scope of this position statement is (1) to review the current evidence on indoor air pollution, its impact on health and particularly on children with allergies and asthma; (2) to give an overview of the European regulatory framework; (3) to describe knowledge gaps, challenges and unmet needs; and (4) to present SynAir‐G′s project goals and propose a roadmap to improve IAQ for children with asthma and allergies.